Assignee
OREXO AB
SE·32 granted patents·24 pending applications·150 citations·filing 2000–2025
Top patents by PatentIndex Score
56 records- 0197US10729687B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2020·Granted Aug 4, 2020·11 cites·17 claims
- 0297US10653690B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2019·Granted May 19, 2020·31 cites·17 claims
- 0396US12268684B2Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2023·Granted Apr 8, 2025·3 cites·35 claims
- 0496US11737980B2Pharmaceutical composition for drug deliveryOREXO AB·Filed 2021·Granted Aug 29, 2023·5 cites·21 claims
- 0596US10898480B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2020·Granted Jan 26, 2021·7 cites·15 claims
- 0695US11957647B2Pharmaceutical composition comprising adrenalineOREXO AB·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0794US12303472B2Pharmaceutical device for use in intranasal administrationOREXO AB·Filed 2023·Granted May 20, 2025·3 cites·30 claims
- 0893US8658198B2Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2013·Granted Feb 25, 2014·15 cites·33 claims
- 0992US10874661B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2018·Granted Dec 29, 2020·2 cites·19 claims
- 1091US11617746B1Method of controlling depression in subjects treated for opioid dependenceOREXO AB·Filed 2021·Granted Apr 4, 2023·2 cites·24 claims
- 1191US2026041682A1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2025·Application pending·0 cites
- 1290US9259421B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2015·Granted Feb 16, 2016·5 cites·24 claims
- 1390US2024390361A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2023·Application pending·0 cites
- 1489US9439900B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2014·Granted Sep 13, 2016·5 cites·18 claims
- 1589US8980305B2Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2013·Granted Mar 17, 2015·9 cites·35 claims
- 1688US8940330B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2012·Granted Jan 27, 2015·5 cites·11 claims
- 1786US11986472B1Method of controlling alcohol consumption in subjects treated for opioid dependenceOREXO AB·Filed 2021·Granted May 21, 2024·1 cites·8 claims
- 1886US8815911B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2013·Granted Aug 26, 2014·11 cites·19 claims
- 1983US7785626B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2003·Granted Aug 31, 2010·18 cites·31 claims
- 2082US7910132B2Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2006·Granted Mar 22, 2011·3 cites·11 claims
- 2178US12472154B2Pharmaceutical composition comprising adrenalineOREXO AB·Filed 2024·Granted Nov 18, 2025·0 cites·31 claims
- 2278US11020387B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Jun 1, 2021·0 cites·14 claims
- 2378US10946010B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Mar 16, 2021·0 cites·21 claims
- 2478US2025205224A1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2025·Application pending·0 cites
- 2577US11433066B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Sep 6, 2022·0 cites·11 claims
- 2677US11020388B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Jun 1, 2021·0 cites·21 claims
- 2776US12138259B1Method of controlling depression in subjects treated for opioid dependenceOREXO AB·Filed 2023·Granted Nov 12, 2024·0 cites·22 claims
- 2876US11883392B2Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2021·Granted Jan 30, 2024·0 cites·35 claims
- 2975US12357573B2Pharmaceutical composition for drug deliveryOREXO AB·Filed 2023·Granted Jul 15, 2025·0 cites·54 claims
- 3075US7815940B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2002·Granted Oct 19, 2010·6 cites·12 claims
- 3174US9345698B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2014·Granted May 24, 2016·2 cites·24 claims
- 3268US2018042920A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2017·Application pending·0 cites
- 3368US2018104235A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2017·Application pending·0 cites
- 3467US2017246161A1Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2016·Application pending·0 cites
- 3566US2025262174A1New pharmaceutical device for use in intranasal administrationOREXO AB·Filed 2025·Application pending·0 cites
- 3666US2014023704A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2013·Application pending·0 cites
- 3766US2008286368A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2008·Application pending·0 cites
- 3866US2016375010A1Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2016·Application pending·0 cites
- 3963US2014030336A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2013·Application pending·0 cites
- 4063US2014335190A1New non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2014·Application pending·0 cites
- 4162US2024408212A1Pharmaceutical composition comprising biopharmaceutical drug compoundsOREXO AB·Filed 2022·Application pending·0 cites
- 4262US2015238482A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2015·Application pending·0 cites
- 4362US2013195976A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2013·Application pending·0 cites
- 4459US2008031941A1Gastric acid secretion inhibiting compositionOREXO AB·Filed 2007·Application pending·0 cites
- 4558US9597281B2Pharmaceutical formulations useful in the treatment of insomniaOREXO AB·Filed 2013·Granted Mar 21, 2017·0 cites·26 claims
- 4658US7771747B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2006·Granted Aug 10, 2010·0 cites·21 claims
- 4756US2013017263A1Gastric acid secretion inhibiting compositionOREXO AB·Filed 2012·Application pending·0 cites
- 4855US9782396B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2016·Granted Oct 10, 2017·0 cites·22 claims
- 4954US2018214437A1New alfentanil composition for the treatment of acute painOREXO AB·Filed 2017·Application pending·0 cites
- 5054US2016151351A1Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2015·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when OREXO AB files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →